Innovative technology performs automatic segmentation and lesion detection in prostate MRI scans to assist in PI-RADS scoring for prostate cancer management TEL AVIV, Israel & SAN JOSE, ...
MRI reports and biopsy pathology reports were extracted from a cohort of 1,360,866 patients with PCa in the VA Cancer Registry System or the VA Corporate Data Warehouse, with 155,570 patients having ...
PI-RADS scores each prostate lesion 1 to 5, with 1 indicating that clinically significant cancer (Gleason score 7 or higher, volume greater than 0.5 cc, and/or extraprostatic extension) is highly ...
Combining PSA density with prostate MRI findings improves the predictive performance of PI-RADS in men without a prior prostate cancer diagnosis. Combining PSA density (PSAD) with prostate magnetic ...
Results from the phase 3 PRECISE trial showed that MRI with targeted biopsies matched or exceeded the accuracy of the current standard for detecting clinically significant prostate cancer. The current ...
Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors A clinical and magnetic resonance imaging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results